Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

February 09, 2023 | Last Trade: US$0.84 0.02 -2.55

Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial.

Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer.

The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added.

Contact Details

Proactive Investors USA

+1 347-449-0879

This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$0.84
Daily Change:	-0.02 -2.55
Daily Volume:	50,912
Market Cap:	US$63.220M

April 09, 2025 Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 March 26, 2025 Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 March 20, 2025 Context Therapeutics Reports Full Year 2024 Operating and Financial Results January 14, 2025 Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 January 13, 2025 Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE